Centrus Q1 2026: GAAP Net Income Drops on Expansion Spend, But Strategic Partnerships and Cost Savings Advance

What happened

Centrus reported Q1 2026 revenue of $76.7M, up from $73.1M a year ago, but GAAP net income fell sharply to $10.0M from $27.2M, reflecting heavy investment in Oak Ridge centrifuge manufacturing expansion and partnerships. Non-GAAP adjusted net income was $23.5M, down from $28.6M, indicating underlying operating performance held up better than GAAP suggests. The company signed strategic collaborations with Fluor and Palantir, with Palantir's AI platform already identifying ~$300M in potential cost savings and manufacturing lead-time reductions. Centrus also raised full-year 2026 revenue guidance and is exploring a HALEU deconversion joint venture with Oklo, underscoring momentum in the domestic enrichment buildout. However, GAAP earnings weakness and the still-contingent nature of $2.3B of backlog (as flagged in the DeepValue report) remind that the investment thesis remains tied to converting 'selected' HALEU awards into obligated funding and delivering a certified-for-construction package at Piketon in 2026.

Implication

Centrus is successfully executing its scale-up strategy, with Fluor and Palantir partnerships de-risking the buildout and potential $300M in savings improving economic returns. However, the $2.3B contingent backlog and GAAP earnings volatility mean that full value realization depends on converting government selections into binding contracts and funded construction milestones over the next 6-12 months.

Thesis delta

The Q1 report confirms that Centrus is investing heavily in expansion, with tangible progress on partnerships and cost savings, which supports the bull case of accelerating domestic enrichment capacity. However, the GAAP earnings miss and continued reliance on contingent government awards keep the risk profile elevated; the base case of execution milestones in 2026 now appears more likely given the Fluor/Palantir collaborations and raised guidance.